CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Drotaverine

屈他维林 杂质对照品Drotaverine Impurities

36 个杂质条目36 impurity entries

本页汇总 屈他维林 的 36 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 36 impurity reference standards of Drotaverine. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 屈他维林(Drotaverine)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesDevelopment and Validation of a Stability-Indicating RP-HPLC Method for the Estimation of Drotaverine Impurities in API and Pharmaceutical Formulation
    Scientia pharmaceutica · 2014 · Thummala VR et al.  ·  PMID 24634845  ·  DOI
  2. 杂质研究Impurity studiesA reversed-phase-high performance liquid chromatography method for simultaneous determination of paracetamol, caffeine, drotaverine HCl and their related impurities with dissolution profiling of their tablets and greenness profile assessment
    Biomedical chromatography : BMC · 2023 · Tawfik SA et al.  ·  PMID 36287616  ·  DOI
  3. 杂质研究Impurity studiesA Novel, Rapid, and Validated Stability-Indicating UPLC Method for the Estimation of Drotaverine Hydrochloride and Ibuprofen Impurities in Oral Solid Dosage Form
    Scientia pharmaceutica · 2015 · Vijay Kumar R et al.  ·  PMID 26839839  ·  DOI
  4. 分析方法Analytical MethodsSmart green spectrophotometric assay of the ternary mixture of drotaverine, caffeine and paracetamol in their pharmaceutical dosage form
    BMC chemistry · 2023 · Ghonim R et al.  ·  PMID 38093380  ·  DOI
  5. 分析方法Analytical MethodsValidation and application of chemometrics-assisted spectrophotometry and liquid chromatography for simultaneous determination of two ternary mixtures containing drotaverine hydrochloride
    Journal of AOAC International · 2010 · El-Gindy A et al.  ·  PMID 20480901

屈他维林 —— 原料药与杂质对照品Drotaverine — drug substance & impurities

共 36 个条目(含原料药本体)36 items incl. the drug substance
Drotaverine Impurity 1 structure
1
屈他维林杂质1Drotaverine Impurity 1
Drotaverine Impurity 1
CAS No.54088-62-9
Chemical FormulaC24H29NO5
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverin Impurity N1 structure
N1
屈他维林杂质N1Drotaverin Impurity N1
Drotaverin Impurity N1
CAS No.56046-20-9
Chemical FormulaC24H27NO5
Purity>95%现货In stock
10mg25mg50mg100mg
Drotaverine Impurity 3 Hydrochloride structure
3
屈他维林杂质3 盐酸盐Drotaverine Impurity 3 Hydrochloride
Drotaverine Impurity 3 Hydrochloride
CAS No.85475-87-2
Chemical FormulaC22H27NO4·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 3 structure
3
屈他维林杂质3Drotaverine Impurity 3
Drotaverine Impurity 3
CAS No.85475-88-3
Chemical FormulaC22H27NO4
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 4 structure
4
屈他维林杂质4Drotaverine Impurity 4
Drotaverine Impurity 4
CAS No.38464-04-9
Chemical FormulaC12H16O4
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 5 structure
5
屈他维林杂质5Drotaverine Impurity 5
Drotaverine Impurity 5
CAS No.61381-04-2
Chemical FormulaC12H19NO2
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 6 structure
6
屈他维林杂质6Drotaverine Impurity 6
Drotaverine Impurity 6
CAS No.6298-46-0
Chemical FormulaC24H33NO5
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 7  (Mixture of E/Z-isomers) structure
7
屈他维林杂质7 (混合E/Z构型)Drotaverine Impurity 7 (Mixture of E/Z-isomers)
Drotaverine Impurity 7 (Mixture of E/Z-isomers)
CAS No.55410-09-8
Chemical FormulaC22H26N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 8 (Mixture of E/Z-isomers) structure
8
屈他维林杂质8 (混合E/Z构型)Drotaverine Impurity 8 (Mixture of E/Z-isomers)
Drotaverine Impurity 8 (Mixture of E/Z-isomers)
CAS No.864820-88-2
Chemical FormulaC22H25NO5
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 9 (Mixture of E/Z-isomers) structure
9
屈他维林杂质9 (混合E/Z构型)Drotaverine Impurity 9 (Mixture of E/Z-isomers)
Drotaverine Impurity 9 (Mixture of E/Z-isomers)
CAS No.864818-60-0
Chemical FormulaC22H25NO5
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 11 structure
11
屈他维林杂质11Drotaverine Impurity 11
Drotaverine Impurity 11
CAS No.121280-59-9
Chemical FormulaC26H33NO5
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 13 structure
13
屈他维林杂质13Drotaverine Impurity 13
Drotaverine Impurity 13
CAS No.885957-46-0
Chemical FormulaC12H18N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 17 structure
17
屈他维林杂质17Drotaverine Impurity 17
Drotaverine Impurity 17
CAS No.92157-09-0
Chemical FormulaC13H18O4
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 18 structure
18
屈他维林杂质18Drotaverine Impurity 18
Drotaverine Impurity 18
CAS No.69373-87-1
Chemical FormulaC14H20O4
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 19 structure
19
屈他维林杂质19Drotaverine Impurity 19
Drotaverine Impurity 19
CAS No.526190-09-0
Chemical FormulaC12H17NO3
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 20 Hydrobromide structure
20
屈他维林杂质20 溴化氢Drotaverine Impurity 20 Hydrobromide
Drotaverine Impurity 20 Hydrobromide
CAS No.16290-26-9
Chemical FormulaC7H9NO2·HBr
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 20 structure
20
屈他维林杂质20Drotaverine Impurity 20
Drotaverine Impurity 20
CAS No.37491-68-2
Chemical FormulaC7H9NO2
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 21 structure
21
屈他维林杂质21Drotaverine Impurity 21
Drotaverine Impurity 21
CAS No.2050-46-6
Chemical FormulaC10H14O2
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 22 structure
22
屈他维林杂质22Drotaverine Impurity 22
Drotaverine Impurity 22
CAS No.27472-20-4
Chemical FormulaC11H15ClO2
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 24 structure
24
屈他维林杂质24Drotaverine Impurity 24
Drotaverine Impurity 24
CAS No.2754344-55-1
Chemical FormulaC24H31NO5
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 34 structure
34
屈他维林杂质34Drotaverine Impurity 34
Drotaverine Impurity 34
CAS No.27472-21-5
Chemical FormulaC12H15NO2
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 35 structure
35
屈他维林杂质35Drotaverine Impurity 35
Drotaverine Impurity 35
CAS No.26691-28-1
Chemical FormulaC10H12O4
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 36 structure
36
屈他维林杂质36Drotaverine Impurity 36
Drotaverine Impurity 36
CAS No.80018-50-4
Chemical FormulaC10H12O4
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 38 structure
38
屈他维林杂质38Drotaverine Impurity 38
Drotaverine Impurity 38
CAS No.1536475-50-9
Chemical FormulaC22H29NO5
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 41 structure
41
屈他维林杂质41Drotaverine Impurity 41
Drotaverine Impurity 41
CAS No.56190-53-5
Chemical FormulaC22H27NO4
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 44 structure
44
屈他维林杂质44Drotaverine Impurity 44
Drotaverine Impurity 44
CAS No.73530-02-6
Chemical FormulaC22H27NO4
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 46 structure
46
屈他维林杂质46Drotaverine Impurity 46
Drotaverine Impurity 46
CAS No.56632-95-2
Chemical FormulaC16H15NO4
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 47 Hydrochloride structure
47
屈他维林杂质47 盐酸盐Drotaverine Impurity 47 Hydrochloride
Drotaverine Impurity 47 Hydrochloride
CAS No.2544-13-0
Chemical FormulaC12H16N2O2·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 47 structure
47
屈他维林杂质47Drotaverine Impurity 47
Drotaverine Impurity 47
CAS No.54716-90-4
Chemical FormulaC12H16N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 48 structure
48
屈他维林杂质48Drotaverine Impurity 48
Drotaverine Impurity 48
CAS No.854869-48-0
Chemical FormulaC24H35NO4
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 49 structure
49
屈他维林杂质49Drotaverine Impurity 49
Drotaverine Impurity 49
CAS No.468744-60-7
Chemical FormulaC31H29N2O6+·Cl-
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 55 structure
55
屈他维林杂质55Drotaverine Impurity 55
Drotaverine Impurity 55
CAS No.2543-46-6
Chemical FormulaC12H16N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 59 structure
59
屈他维林杂质59Drotaverine Impurity 59
Drotaverine Impurity 59
CAS No.68729-54-4
Chemical FormulaC12H16N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 61 structure
61
屈他维林杂质61Drotaverine Impurity 61
Drotaverine Impurity 61
CAS No.771560-34-0
Chemical FormulaC13H14N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 63 structure
63
屈他维林杂质63Drotaverine Impurity 63
Drotaverine Impurity 63
CAS No.855199-57-4
Chemical FormulaC22H26O7
Purity>95%询价On request
10mg25mg50mg100mg
Drotaverine Impurity 70 structure
70
屈他维林杂质70Drotaverine Impurity 70
Drotaverine Impurity 70
CAS No.21088-15-3
Chemical FormulaC24H33NO4
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

屈他维林 —— 研究文献与合成路线Drotaverine — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 屈他维林 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Drotaverine. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. A Novel, Rapid, and Validated Stability-Indicating UPLC Method for the Estimation of Drotaverine Hydrochloride and Ibuprofen Impurities in Oral Solid Dosage Form
    Vijay Kumar R, Rao VU, Anil Kumar N, et al. · Scientia pharmaceutica · 2015 · 被引 3cited 3
  2. Development and Validation of a Stability-Indicating RP-HPLC Method for the Estimation of Drotaverine Impurities in API and Pharmaceutical Formulation
    Thummala VR, Tharlapu SS, Rekulapalli VK, et al. · Scientia pharmaceutica · 2014
  3. Smart chemometrics-assisted spectrophotometric methods for efficient resolution and simultaneous determination of paracetamol, caffeine, drotaverine HCl along with three of their corresponding related impurities
    Tawfik SA, Hegazy MA, El-Ragehy NA, et al. · BMC chemistry · 2023 · 被引 7cited 7
  4. A reversed-phase-high performance liquid chromatography method for simultaneous determination of paracetamol, caffeine, drotaverine HCl and their related impurities with dissolution profiling of their tablets and greenness profile assessment
    Tawfik SA, El-Ragehy NA, Hegazy MA, et al. · Biomedical chromatography : BMC · 2023 · 被引 4cited 4
  5. Spectrophotometric determination of pipazethate HCl, dextromethorphan HBr and drotaverine HCl in their pharmaceutical preparations
    Amin AS, El-Sheikh R, Zahran F, et al. · Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2007 · 被引 14cited 14
  6. Determination of nifuroxazide and drotaverine hydrochloride in pharmaceutical preparations by three independent analytical methods
    Metwally FH, Abdelkawy M, Naguib IA · Journal of AOAC International · 2006 · 被引 11cited 11

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

屈他维林 杂质谱研究要点Drotaverine — impurity profiling notes

下面这些是拿到 屈他维林 的 36 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 36 impurity entries for Drotaverine, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances